1. Introduction {#sec1}
===============

SCACP is an extremely rare cutaneous adnexal neoplasm, of which only less than 50 cases have been described in the literature since its first description in 1980 by Dissanayake et al. \[[@B1]\]. SCACP is originated from apocrine or eccrine sweat glands and often presents as a nodular mass in the scalp as well as other parts of the body \[[@B2]\]. Although its histopathologic features have been well described \[[@B3]--[@B5]\], the optimal treatment has not yet been established because of the rarity of the tumor. WLE has been the preferred treatment for localized SCACP \[[@B6]\]; however, there is no standard systemic therapy for the unresectable or metastatic disease. In addition, the genomic profile of SCACP has not yet been reported. Herein, we report a case of metastatic SCACP, its genomic profile, PD-L1 status, and response to the multimodal treatment.

2. Case Presentation {#sec2}
====================

74-year-old otherwise healthy male presented with a 3 × 4 cm^2^ painful nodule on the upper back. The lesion was initially diagnosed as a lipoma and surgically removed. However, six months after resection, the patient developed thoracic back pain. Thoracic MRI revealed an infiltrative mass of T3 to T5 vertebrae. A WLE with T3 to T5 laminectomy was performed, and the excision specimen was interpreted as squamous cell carcinoma. One year later, his back pain reemerged, and the patient developed bilateral lower extremity weakness, prompted a repeat MRI, which demonstrated 4.7 × 5.4 × 7.5 cm^3^ soft tissue cystic mass at the T3 to T5 vertebral level invading the neural foramina bilaterally as well as an enlarged right axillary lymph node ([Figure 1(a)](#fig1){ref-type="fig"}). Fine needle aspiration of the lymph node showed a high-grade carcinoma showing papillary and tubular architectural features. The tumor cells were immunoreactive for high molecular weight keratin (CK5/6), wide spectrum cytokeratin, and p63 immuno-stains ([Figure 1(b)](#fig1){ref-type="fig"}). Taken together, the morphologic and immunophenotypic features supported the diagnosis of SCACP.

The patient was deemed not a surgical candidate and was treated with three cycles of carboplatin and paclitaxel with concurrent intensity-modulated radiation therapy (IMRT), which resulted in disease stabilization and significant improvement of his neurological symptoms. However, he developed right arm pain and weakness within a year of treatment, and the repeat imaging showed an increase in size of the right axillary lymph node and stable disease in his spine ([Figure 2](#fig2){ref-type="fig"}). The lymph node was resected and sent for the next generation sequencing (The FoundationOne assay interrogates 315 genes as well as introns of 28 genes involved in rearrangements), which revealed a total of 18 genomic alterations associated with potential benefit from targeted therapeutics ([Table 1](#tab1){ref-type="table"}). PD-L1 expression was identified in 70% of tumor cells using Tumor Proportion Score (TPS). Patient was offered checkpoint inhibitor-based therapy that he declined.

3. Discussion {#sec3}
=============

SCACP is an extremely rare cutaneous neoplasm of the apocrine or eccrine sweat glands. Due to the rarity of this entity, clinical and pathologic diagnosis is challenging. However, solid and cystic glandular structures with cribriform and tubular architecture along with CK5/6, pankeratin, and p63 immuno-profile set apart SCACP from other cutaneous malignancies.

WLE has been the mainstay treatment for localized SCACP; however, high recurrence rate (30-40%) following surgery has been reported \[[@B4], [@B6]\]. For unresectable or metastatic disease, no standard treatment has yet been established. To date, there has been only one case reported, in which a cisplatin chemoradiation was delivered, and the patient was rendered disease free for 11 months \[[@B7]\]. Our patient achieved disease control for 12 months with carboplatin and paclitaxel concurrently with IMRT.

To determine potential therapeutic strategies, the molecular profile of the tumor was requested, which revealed 18 genomic alterations associated with potential clinical benefit ([Table 1](#tab1){ref-type="table"}). Among these alterations, ERBB4 R293W has been previously observed in several cancers including malignant melanoma, which was found to be sensitive to the ERBB inhibitor, lapatinib *in vitro* \[[@B8]\]. Another genomic alteration which may indicate biological and therapeutic relevance is PIK3CA E453K \[[@B9]\]. PIK3CA activating mutations or amplification may predict sensitivity to inhibitors of PI3K or its downstream signaling pathway (the PI3K/Akt/mTOR pathway) \[[@B10]\]. Moreover, the impaired function of CDKN2A results in cell cycle dysregulation \[[@B11]\] and clinical benefit from CDK4/6 inhibitors has been shown in patients harboring CDKN2A alterations \[[@B12], [@B13]\]. Although these are potentially interesting findings, further studies will need to be performed to validate these genomic alterations.

Lastly, the efficacy of immunotherapy in the treatment of SCACP has not yet been demonstrated. To our knowledge, this is the first report of PD-L1 expression in SCACP, and the result suggests the possibility of using checkpoint inhibitors in this otherwise difficult to treat disease.

4. Conclusion {#sec4}
=============

We report a case of metastatic SCACP, its histopathological and genomic characterization, and response to the combined modality of treatment. The opportunity of targeted therapeutics and immunotherapy exist as for metastatic SCACP. Reporting molecular profile of the rare tumors with no established standard treatment options should be encouraged.
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![Radiologic and histologic appearance of syringocystadenocarcinoma papilliferum. (a) (I) Magnetic resonance imaging showing soft tissue mass in the thoracic spine. (II) Axial computed tomography (CT) scan showing tumor invasion into the vertebrae at T4 level. (III) Axial CT scan showing tumor invasion into the vertebrae at T2 level and enlarged right axillary lymph node. (b) (I) Lymph node with metastatic tumor, H&E stain, 40x. (II) Solid and glandular structures with warty architecture, lined by poorly-differentiated epithelium, H&E stain, 100x. (III) Clusters and nests of highly pleomorphic cells with bizarre irregular nuclei and permanent nucleoli, entrapped in fibrotic stroma, consistent with carcinoma, H&E stain, 400x. (IV) Metastatic carcinoma cells are highlighted by immune-stain (right lower corner); residual uninvolved lymph node shows no immunopositivity (left upper corner), wide spectrum cytokeratin immunostain, 100x.](CRIONM2020-9056209.001){#fig1}

![Positron emission tomography (PET) scan images 12 months after chemoradiotherapy. Hypermetabolic activity in the left paraspinal region at the level of T4-T5 (I), in the right axilla (II), and in the left sixth rib medially (III).](CRIONM2020-9056209.002){#fig2}

###### 

Molecular characterization of the patient\'s tumor.

  Gene     Gene function                                                  Mutation          Mutation description   Targeted therapy
  -------- -------------------------------------------------------------- ----------------- ---------------------- --------------------------------
  ARID2    Activation of gene expression by nuclear receptors             Q725^∗^           Nonsense               None
  CDKN2A   Tumor suppressor                                               p16INK4a Q50^∗^   Nonsense               Palbociclib
  ERBB4    Cell proliferation and apoptosis                               R393W             Missense               Afatinib, Erlotinib, Lapatinib
  FAT1     Inhibition of transcriptional activity                         G758fs            Frameshift             None
  FGF10    Regulation of cell growth, tumor growth and invasion           Amplification     ---                    None
  FGFR1    Regulation of the cell cycle and angiogenesis                  Q775^∗^           Nonsense               Ponatinib, Pazopanib
  GNA11    Modulation of transmembrane signaling system                   R183C             Missense               Trametinib
  KDM5C    Control gene expression                                        Q919^∗^           Nonsense               None
  MAGI2    Inhibition of cell migration and proliferation                 Q117^∗^           Nonsense               None
  NFKBIA   Tumor suppressor                                               Amplification     ---                    None
  NOTCH1   Regulation of cell fate, proliferation and apoptosis           6181-1G \>A       Intronic               None
  PIK3CA   Regulation of cell growth, proliferation, and survival         E453K             Missense               Everolimus, Temsirolimus
  RAC1     Regulation of tumor angiogenesis, metastasis and cell growth   P29S^∗^           Nonsense               None
  RICTOR   Encoding an mTOR-binding protein                               Amplification     ---                    Omipalisib
  SLIT2    Tumor suppressor                                               D1445H            Missense               None
  TERT     Regulation of chromosomal length                               124C \>T          Intronic               None
  TP53     Tumor suppressor                                               Q331^∗^           Nonsense               Adavosertib
  TP53     Tumor suppressor                                               Q375^∗^           Nonsense               Adavosertib
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